The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global CD257 Antibody Market Research Report 2024
Synopsis
Mouse anti Human CD257 antibody, clone T7-241 recognizes human CD257 otherwise known as BAFF/BLyS. CD257 is a 285 amino acid type II transmembrane protein and member of the tumor necrosis factor (TNF) superfamily of ligands, which acts as a B and T cell stimulator and plays a role in the development of autoimmune diseases such as systemic lupus erythematosus.
CD257 is expressed by monocytes, macrophages, T cells and dendritic cells and acts through binding to CD267 (TACI), CD269 (BCMA) and CD268 (BAFFR) receptors, the latter interaction playing a critical role in the activation, survival, differentiation and proliferation of B cells.
Global CD257 Antibody market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CD257 Antibody market research.
Growing patient base, launch of CD257 antibody drugs, increasing penetration of antibody drugs, and continuous regulation across the biopharmaceutical industry are the key factors driving the increase in CD257 antibody market revenue.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CD257 Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Thermo Fisher Scientific
BosterBio
Enzo Life Sciences
Proteintech Group
QED Bioscience
RayBiotech
BioLegend
Biointron Biological
GeneTex
United States Biological
Miltenyi Biotec
Abcam
ichorbio
Affinity Biosciences
OriGene Technologies
Cell Signaling Technology
Leinco Technologies
Creative Diagnostics
Biobyt
Jingjie PTM BioLab
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CD257 Antibody report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Mouse anti Human CD257 antibody, clone T7-241 recognizes human CD257 otherwise known as BAFF/BLyS. CD257 is a 285 amino acid type II transmembrane protein and member of the tumor necrosis factor (TNF) superfamily of ligands, which acts as a B and T cell stimulator and plays a role in the development of autoimmune diseases such as systemic lupus erythematosus.
CD257 is expressed by monocytes, macrophages, T cells and dendritic cells and acts through binding to CD267 (TACI), CD269 (BCMA) and CD268 (BAFFR) receptors, the latter interaction playing a critical role in the activation, survival, differentiation and proliferation of B cells.
Global CD257 Antibody market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CD257 Antibody market research.
Growing patient base, launch of CD257 antibody drugs, increasing penetration of antibody drugs, and continuous regulation across the biopharmaceutical industry are the key factors driving the increase in CD257 antibody market revenue.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CD257 Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Thermo Fisher Scientific
BosterBio
Enzo Life Sciences
Proteintech Group
QED Bioscience
RayBiotech
BioLegend
Biointron Biological
GeneTex
United States Biological
Miltenyi Biotec
Abcam
ichorbio
Affinity Biosciences
OriGene Technologies
Cell Signaling Technology
Leinco Technologies
Creative Diagnostics
Biobyt
Jingjie PTM BioLab
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CD257 Antibody report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CD257 Antibody Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Monoclonal
1.2.3 Polyclonal
1.3 Market by Application
1.3.1 Global CD257 Antibody Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Immunochemistry (IHC)
1.3.3 Immunofluorescence (IF)
1.3.4 Immunoprecipitation (IP)
1.3.5 Western Blot (WB)
1.3.6 ELISA
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CD257 Antibody Market Perspective (2018-2029)
2.2 CD257 Antibody Growth Trends by Region
2.2.1 Global CD257 Antibody Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 CD257 Antibody Historic Market Size by Region (2018-2023)
2.2.3 CD257 Antibody Forecasted Market Size by Region (2024-2029)
2.3 CD257 Antibody Market Dynamics
2.3.1 CD257 Antibody Industry Trends
2.3.2 CD257 Antibody Market Drivers
2.3.3 CD257 Antibody Market Challenges
2.3.4 CD257 Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CD257 Antibody Players by Revenue
3.1.1 Global Top CD257 Antibody Players by Revenue (2018-2023)
3.1.2 Global CD257 Antibody Revenue Market Share by Players (2018-2023)
3.2 Global CD257 Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CD257 Antibody Revenue
3.4 Global CD257 Antibody Market Concentration Ratio
3.4.1 Global CD257 Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CD257 Antibody Revenue in 2022
3.5 CD257 Antibody Key Players Head office and Area Served
3.6 Key Players CD257 Antibody Product Solution and Service
3.7 Date of Enter into CD257 Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CD257 Antibody Breakdown Data by Type
4.1 Global CD257 Antibody Historic Market Size by Type (2018-2023)
4.2 Global CD257 Antibody Forecasted Market Size by Type (2024-2029)
5 CD257 Antibody Breakdown Data by Application
5.1 Global CD257 Antibody Historic Market Size by Application (2018-2023)
5.2 Global CD257 Antibody Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America CD257 Antibody Market Size (2018-2029)
6.2 North America CD257 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CD257 Antibody Market Size by Country (2018-2023)
6.4 North America CD257 Antibody Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CD257 Antibody Market Size (2018-2029)
7.2 Europe CD257 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CD257 Antibody Market Size by Country (2018-2023)
7.4 Europe CD257 Antibody Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CD257 Antibody Market Size (2018-2029)
8.2 Asia-Pacific CD257 Antibody Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CD257 Antibody Market Size by Region (2018-2023)
8.4 Asia-Pacific CD257 Antibody Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CD257 Antibody Market Size (2018-2029)
9.2 Latin America CD257 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CD257 Antibody Market Size by Country (2018-2023)
9.4 Latin America CD257 Antibody Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CD257 Antibody Market Size (2018-2029)
10.2 Middle East & Africa CD257 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CD257 Antibody Market Size by Country (2018-2023)
10.4 Middle East & Africa CD257 Antibody Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Detail
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific CD257 Antibody Introduction
11.1.4 Thermo Fisher Scientific Revenue in CD257 Antibody Business (2018-2023)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 BosterBio
11.2.1 BosterBio Company Detail
11.2.2 BosterBio Business Overview
11.2.3 BosterBio CD257 Antibody Introduction
11.2.4 BosterBio Revenue in CD257 Antibody Business (2018-2023)
11.2.5 BosterBio Recent Development
11.3 Enzo Life Sciences
11.3.1 Enzo Life Sciences Company Detail
11.3.2 Enzo Life Sciences Business Overview
11.3.3 Enzo Life Sciences CD257 Antibody Introduction
11.3.4 Enzo Life Sciences Revenue in CD257 Antibody Business (2018-2023)
11.3.5 Enzo Life Sciences Recent Development
11.4 Proteintech Group
11.4.1 Proteintech Group Company Detail
11.4.2 Proteintech Group Business Overview
11.4.3 Proteintech Group CD257 Antibody Introduction
11.4.4 Proteintech Group Revenue in CD257 Antibody Business (2018-2023)
11.4.5 Proteintech Group Recent Development
11.5 QED Bioscience
11.5.1 QED Bioscience Company Detail
11.5.2 QED Bioscience Business Overview
11.5.3 QED Bioscience CD257 Antibody Introduction
11.5.4 QED Bioscience Revenue in CD257 Antibody Business (2018-2023)
11.5.5 QED Bioscience Recent Development
11.6 RayBiotech
11.6.1 RayBiotech Company Detail
11.6.2 RayBiotech Business Overview
11.6.3 RayBiotech CD257 Antibody Introduction
11.6.4 RayBiotech Revenue in CD257 Antibody Business (2018-2023)
11.6.5 RayBiotech Recent Development
11.7 BioLegend
11.7.1 BioLegend Company Detail
11.7.2 BioLegend Business Overview
11.7.3 BioLegend CD257 Antibody Introduction
11.7.4 BioLegend Revenue in CD257 Antibody Business (2018-2023)
11.7.5 BioLegend Recent Development
11.8 Biointron Biological
11.8.1 Biointron Biological Company Detail
11.8.2 Biointron Biological Business Overview
11.8.3 Biointron Biological CD257 Antibody Introduction
11.8.4 Biointron Biological Revenue in CD257 Antibody Business (2018-2023)
11.8.5 Biointron Biological Recent Development
11.9 GeneTex
11.9.1 GeneTex Company Detail
11.9.2 GeneTex Business Overview
11.9.3 GeneTex CD257 Antibody Introduction
11.9.4 GeneTex Revenue in CD257 Antibody Business (2018-2023)
11.9.5 GeneTex Recent Development
11.10 United States Biological
11.10.1 United States Biological Company Detail
11.10.2 United States Biological Business Overview
11.10.3 United States Biological CD257 Antibody Introduction
11.10.4 United States Biological Revenue in CD257 Antibody Business (2018-2023)
11.10.5 United States Biological Recent Development
11.11 Miltenyi Biotec
11.11.1 Miltenyi Biotec Company Detail
11.11.2 Miltenyi Biotec Business Overview
11.11.3 Miltenyi Biotec CD257 Antibody Introduction
11.11.4 Miltenyi Biotec Revenue in CD257 Antibody Business (2018-2023)
11.11.5 Miltenyi Biotec Recent Development
11.12 Abcam
11.12.1 Abcam Company Detail
11.12.2 Abcam Business Overview
11.12.3 Abcam CD257 Antibody Introduction
11.12.4 Abcam Revenue in CD257 Antibody Business (2018-2023)
11.12.5 Abcam Recent Development
11.13 ichorbio
11.13.1 ichorbio Company Detail
11.13.2 ichorbio Business Overview
11.13.3 ichorbio CD257 Antibody Introduction
11.13.4 ichorbio Revenue in CD257 Antibody Business (2018-2023)
11.13.5 ichorbio Recent Development
11.14 Affinity Biosciences
11.14.1 Affinity Biosciences Company Detail
11.14.2 Affinity Biosciences Business Overview
11.14.3 Affinity Biosciences CD257 Antibody Introduction
11.14.4 Affinity Biosciences Revenue in CD257 Antibody Business (2018-2023)
11.14.5 Affinity Biosciences Recent Development
11.15 OriGene Technologies
11.15.1 OriGene Technologies Company Detail
11.15.2 OriGene Technologies Business Overview
11.15.3 OriGene Technologies CD257 Antibody Introduction
11.15.4 OriGene Technologies Revenue in CD257 Antibody Business (2018-2023)
11.15.5 OriGene Technologies Recent Development
11.16 Cell Signaling Technology
11.16.1 Cell Signaling Technology Company Detail
11.16.2 Cell Signaling Technology Business Overview
11.16.3 Cell Signaling Technology CD257 Antibody Introduction
11.16.4 Cell Signaling Technology Revenue in CD257 Antibody Business (2018-2023)
11.16.5 Cell Signaling Technology Recent Development
11.17 Leinco Technologies
11.17.1 Leinco Technologies Company Detail
11.17.2 Leinco Technologies Business Overview
11.17.3 Leinco Technologies CD257 Antibody Introduction
11.17.4 Leinco Technologies Revenue in CD257 Antibody Business (2018-2023)
11.17.5 Leinco Technologies Recent Development
11.18 Creative Diagnostics
11.18.1 Creative Diagnostics Company Detail
11.18.2 Creative Diagnostics Business Overview
11.18.3 Creative Diagnostics CD257 Antibody Introduction
11.18.4 Creative Diagnostics Revenue in CD257 Antibody Business (2018-2023)
11.18.5 Creative Diagnostics Recent Development
11.19 Biobyt
11.19.1 Biobyt Company Detail
11.19.2 Biobyt Business Overview
11.19.3 Biobyt CD257 Antibody Introduction
11.19.4 Biobyt Revenue in CD257 Antibody Business (2018-2023)
11.19.5 Biobyt Recent Development
11.20 Jingjie PTM BioLab
11.20.1 Jingjie PTM BioLab Company Detail
11.20.2 Jingjie PTM BioLab Business Overview
11.20.3 Jingjie PTM BioLab CD257 Antibody Introduction
11.20.4 Jingjie PTM BioLab Revenue in CD257 Antibody Business (2018-2023)
11.20.5 Jingjie PTM BioLab Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
